Navigation Links
SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
Date:11/7/2008

omers, competition, government regulation and approvals, and general economic conditions. For example, if our clinical trials are not successful or take longer to complete than we expect, we may not be able to develop and commercialize our products. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission. Such filings are available on our website or at http://www.sec.gov. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstance.

Financial Information

SCOLR Pharma, Inc.

BALANCE SHEET

September 30, December 31,

2008 2007

(Unaudited)

ASSETS

Current Assets

Cash and cash equivalents $8,908,986 $11,825,371

Accounts receivable 244,214 225,900

Interest and other receivables - 16

Prepaid expenses and other assets 323,407 432,213

Total current assets 9,476,607 12,474,500

Property and Equipment - net of

accumulated depreciation of

$1,213,775 and $964,738, respectively 502,510 748,931

Intangible assets - net of

accumulated amortization of $443,435

and $385,452, respectively 522,403 464
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
2. FluoroPharma, Inc. to Report Preclinical Data on Alzheimers Disease and Prostate Cancer PET Imaging Agents
3. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
4. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
5. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
6. Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
7. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
8. Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
9. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
10. Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio
11. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014  Tasly Pharmaceuticals, Inc., the ... medicine, announced today the launch of Deepure. ... to address men and women concerned with supporting ... into old age while helping keep their health ... whole-food and herb-based formulas, namely, ProHeart PLUS, ImmunoPower ...
(Date:9/30/2014)... , Sept. 30, 2014 Arbor Pharmaceuticals, ... Summary Global Markets Direct,s, ,Arbor Pharmaceuticals, LLC. ... overview of the Arbor Pharmaceuticals, LLC.,s pharmaceutical research ... information on the current therapeutic developmental pipeline of ... various stages, therapeutics assessment by drug target, mechanism ...
(Date:9/30/2014)... Sept. 30, 2014  Decision Resources Group finds that the ... , China , India ... a strong rate through 2023. Dental implant procedure volumes will grow ... awareness rises. Other key findings from Decision Resources Group,s ... market: , Dental implant penetration: Penetration of dental ...
Breaking Medicine Technology:Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3
... Study Comparing Leading Hepatitis C Therapies Provides ... Insights to Help Guide Clinical Practice, MILAN, Italy, ... first large, randomized, clinical study comparing the,leading therapies for ... Meeting of the European Association for the Study of ...
... of treatment with R7128 1500mg BID with Pegasys(R) plus Copegus(R) -, - Safety and ... ... presentation available on Pharmasset website -, - Conference call scheduled for Friday, April 25, 2008 at ... and 7:00 PM CEST (Milan) -, ...
Cached Medicine Technology:Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 2Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 3Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 4Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 5Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 6Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 7Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 8Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 9Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 10Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 2Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 3Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 4Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 5Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 6
(Date:10/1/2014)... research co-funded by the Engineering and Physical Sciences ... of the UK,s vital industrial control systems which ... electricity grid, and the rail network. , ... from hackers or malware infiltrating the systems behind ... Institute in Trustworthy Industrial Control Systems (RITICS), based ...
(Date:10/1/2014)... 01, 2014 Marriagelifeinsurance.com has released ... insurance for retired couples. , Senior citizens can ... security for their loved ones. A joint policy is ... persons pass away. , Life insurance can be ... insurance can even be purchased online, as the application ...
(Date:10/1/2014)... Phoseon Technology, the pioneer in developing ... business worldwide. This rapid growth includes increased hiring for ... efforts. The company has experienced average annual growth rates ... this growth to continue in the future as new ... , “We are very pleased that UV ...
(Date:10/1/2014)... 01, 2014 Beverly Hills licensed Clinical ... is celebrating 20 years of private practice in her ... people to achieve greater joy and fulfillment in their ... warning signs and suggestions for anyone who suspects they ... “Believe it or not, it’s not always easy ...
(Date:10/1/2014)... Anti Aging Clinic (AntiAgingClinic.ca), the Greater ... of choice, is announcing a discounted cost on Botox ... , “We’re doing this because we want to give ... skin clinic in Toronto,” says Dr. Brian Sieber, founder ... Anti Aging Clinic, including laser facials, genesis laser facials, ...
Breaking Medicine News(10 mins):Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2
... June 13 (Pink Sheets: ICTY) As of,June 11, ... that is,going to completely revamp the company and move ... very tight and secure team of corporate,individuals are in ... must be addressed prior to the release of any ...
... HILL, N.C., June 13 Market competition ... interest of the most highly,qualified clinical investigators. ... clinical investigators to their studies win an ... Best Practices, LLC,s white paper "Recruiting and ...
... could detect disease sooner, when it,s more treatable , , FRIDAY, ... development of pancreatic cancer have been identified by U.S. researchers, ... to develop a blood test to detect this type of ... , "Our team identified, for the first time, protein ...
... Paris, France, Friday 13 June 2008: Rheumatoid ... (PsA) patients should undergo compulsory cardiovascular (CV) risk ... adapted to the increased CV risk in inflammatory ... ,Cardiovascular Risk Management in RA, recommended today at ...
... End of Life Urges Congress to Preserve ... Compassionate End-of-Life Care, WASHINGTON, June ... Payment Advisory Commission (MedPAC),reported that the rapid growth of the Medicare ... and more spending per,beneficiary. According to the report, "Evaluating Medicare,s Hospice,Benefit," ...
... 13 June 2008: A new DNA microarray chip can ... arthritis (RA), as presented today at EULAR 2008, the ... Paris, France. The chip (called the ,ARTchip,) has yielded ... in anticipating likely disease progression and prognosis and thereby ...
Cached Medicine News:Health News:EyeCity.com, Inc. Changes Ownership and Moves Into a New Direction 2Health News:Pancreatic Cancer Biomarkers Found 2Health News:CV risk management should be mandatory in RA and other types of inflammatory rheumatic disease 2Health News:CV risk management should be mandatory in RA and other types of inflammatory rheumatic disease 3Health News:More Data Needed Before Changing Medicare Hospice Funding, Report Finds 2Health News:More Data Needed Before Changing Medicare Hospice Funding, Report Finds 3Health News:Novel DNA microarray chip predicts functional impairment and remission in rheumatoid arthritis 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: